Preblick Ryan 4

What Happened
Ryan Preblick, Chief Financial Officer of Indivior Pharmaceuticals (INDV), disposed of 36,000 shares on June 8, 2026 in an open-market/private sale at $37.70 per share, for total proceeds of $1,357,200. This was a sale (S) and not a purchase — sales by insiders are often routine cashing-out events rather than a signal of company prospects.

Key Details

• Transaction date: 2026-06-08; price: $37.70 per share; shares sold: 36,000; total value: $1,357,200.
• Transaction type/code: Sale (S).
• Reporting/filing date: Form 4 filed 2026-06-10 — appears to have been filed within the standard reporting window.
• Footnote: Sale was effected pursuant to a Rule 10b5-1 trading plan adopted March 6, 2026 (pre‑scheduled trade).
• Shares owned after transaction: Not specified in the information provided in this summary.

Context
A 10b5-1 plan means the sale was pre-arranged, which is common and reduces the implication that the trade was based on material nonpublic information or a change in view. For retail investors, purchases typically carry more weight as a confidence signal; planned insider sales like this are usually routine liquidity events.